Navigation Links
ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
Date:1/26/2011

MOUNTAIN VIEW, Calif., Jan. 26, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.  This receptor is known to regulate inflammatory cells in disease such as psoriasis. CCX832 is the fourth and final drug candidate discovered and developed by ChemoCentryx under the Company's alliance with GlaxoSmithKline (GSK) to identify molecules targeting four specific chemokine and chemoattractant receptors.  The initiation of this Phase I clinical trial triggered a $10 million milestone payment from GSK.

"With the successful conclusion of the discovery phase of our GSK alliance, we are intensifying and expanding our efforts in our other ongoing programs that are entirely outside the GSK alliance," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "These programs include a novel drug targeting the chemokine receptor CCR2, which has just successfully completed a Phase 2 clinical trial and a cancer program targeting the receptor CXCR7, which was discovered by ChemoCentryx scientists. In addition, we are advancing programs in liver and kidney disease and in the next generation of medicines for inflammatory bowel disease, all of which offer vast opportunities in largely unmet medical needs."

About ChemR23/CCX832

The ligand for ChemR23, chemerin, is a widely expressed protein that circulates in human plasma in an inactive state and becomes biologically activated in inflammatory settings. There is building evidence that suggests chemerin may serve as a biological alarm signal that, under conditions of tissue injury, recruits ChemR23-expressing immune cells. Diseases such as psoriasis are also associated with elevated levels of activated chemerin. In preclinical studies, CCX832 has demonstrated the ability to successfully block
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
3. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
4. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
5. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
6. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
9. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
10. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
11. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... NEW YORK , Sept. 1, 2014 /PRNewswire/ ... report is available in its catalogue:  Drug ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html ... diseases, such as cancer requires extensive expenditure, in ... first step in designing a new drug involves ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... Aug. 29, 2014 Pomerantz LLP has filed ... the "Company") (NASDAQ: EDAP ) and certain ... States District Court, Southern District of New ... behalf of a class consisting of all persons or ... and July 30, 2014, inclusive (the "Class Period"). This class ...
Breaking Medicine Technology:Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11Drug Discovery Technologies - A Global Market Overview 12Drug Discovery Technologies - A Global Market Overview 13Drug Discovery Technologies - A Global Market Overview 14X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
... Epocal, Inc., a leading edge provider of point of ... and Drug Administration (FDA) clearance to market its new lactate ... the epoc System are used to evaluate acid-base status and ... of the blood).  The addition of lactate to the epoc ...
... , ANN ARBOR, Mich. , June 15 ... announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, ... a full array of microbiology testing.  Adeona believes that ... HartLab,s revenues in the current quarter and beyond and ...
Cached Medicine Technology:Epocal Announces FDA Clearance of Lactate Test 2Adeona Announces HartLab Expansion Into Microbiology Testing Services 2Adeona Announces HartLab Expansion Into Microbiology Testing Services 3Adeona Announces HartLab Expansion Into Microbiology Testing Services 4Adeona Announces HartLab Expansion Into Microbiology Testing Services 5
(Date:9/1/2014)... September 01, 2014 An operating theatre ... hospital for performing surgical operations. An operating room comprises ... surgical booms, operating room lights, imaging displays as well ... report by Transparency Market Research, a U.S.-based market research ... reach USD 4.5 billion by 2019. , According ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. ... given to two American aid workers successfully cured a group ... researchers report. The drug, ZMapp, prompted recovery in all ... the medication until five days after infection. ZMapp even ... or even hours away from death, said study senior author ...
(Date:9/1/2014)... D.C. (PRWEB) September 01, 2014 The ... pleased to announce that Dawn Bazarko, DNP, MPH, RN, ... Fellows of the American Academy of Nursing. They will ... MBA, RN-BC, CCM, FACHE, whose induction we reported last ... October 18, 2014, during the 2014 American Academy of ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... August 31, 2014 Daily Gossip reveals ... resource and community that gives members access to thousands ... , This online resource aims to help both people ... as artists who are looking for inspiration in creating ... about Tattoo Me Now by visiting the official website ...
Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... ARAY ), a global leader in the field of radiosurgery, ... Needham Life Sciences Conference in New York City, on Wednesday, June ... , A live webcast of the presentation will be available online ... http://www.accuray.com . The webcast replay ...
... to 25% drop in test scores, study found , THURSDAY, ... reason to be annoyed at other people,s cell phones, researchers ... ringtone can impair thinking, at least briefly. , Students unwittingly ... after a fellow "student,s" phone went off. , The finding ...
... to growing list of solutions available to help companies and ... , DEERFIELD, Ill., June 4 Knowledge and prevention are ... may look or feel healthy, you may not know about ... , , That is why Focused Health Solutions, a ...
... risk while ensuring accurate payments and compliance with Medicare standards , ... have ever wondered how to integrate Medicare Risk Adjustment with their ... latest release from Storan Technologies Inc. (STI). ... Merlin Medicare Risk Adjustment 6.0 (TM), a Web-based software solution ...
... June 4 Abbott (NYSE: ABT ) ... a New Drug Application (NDA) to the U.S. Food ... the treatment of mixed dyslipidemia, a combination of two ... "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" ...
... , SUNNYVALE, Calif., June 4 - Cepheid (Nasdaq: ... for its symposium, "On-Demand HAI Testing: Good Medicine and ... 2009 Association for Professionals in Infection Control (APIC) annual ... - 10th. Cepheid,s GeneXpert(R) Systems and menu of molecular ...
Cached Medicine News:Health News:Accuray Incorporated to Present at Eighth Annual Needham Life Sciences Conference 2Health News:Stranger's Cell Phone Ring May Thwart Your Thinking 2Health News:Stranger's Cell Phone Ring May Thwart Your Thinking 3Health News:Focused Health Solutions Helps Make Preventative Health Screenings Simple and More Affordable 2Health News:Focused Health Solutions Helps Make Preventative Health Screenings Simple and More Affordable 3Health News:St. Louis Firm Brings Medicare Risk Adjustment to iPhone 2Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 2Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 3Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 4Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 5Health News:Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference 2Health News:Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: